The partnership integrates Twist’s antibody services directly into the TuneLab ecosystem. By utilizing preferred protocols, researchers can now leverage TuneLab’s artificial intelligence and machine learning models to accelerate the selection of candidate molecules. This workflow allows for a more efficient transition from digital prediction to the generation of essential wet lab data.
In section Market Quotes
Twist Bioscience Stocks Surge Following Eli Lilly Partnership
Shares of Twist Bioscience climbed 5% to $144.90 on Wednesday, capping a year of remarkable growth that saw the company's valuation quadruple. This market jump follows the announcement of a strategic collaboration with Lilly TuneLab, the drug discovery platform operated by pharmaceutical giant Eli Lilly.
Investors have responded favorably to the expansion of Twist’s technical footprint within the drug discovery pipeline. With the stock currently trading at $144.90, the deal underscores the growing demand for automated, AI-driven platforms in modern biopharmaceutical research.
Comments (0)
No comments yet. Be the first!